Pharmacist New Drugs | Patient Safety | Treatment Guidelines Podcast 30 credit minutes

Ranitidine — once withdrawn from the market over safety concerns — was recently re-approved by the FDA in a reformulated version, raising important questions for pharmacists and patients alike. This course outlines the FDA’s recent approval, reviews the reformulated product’s changes (including manufacturing and labeling), and examines practical considerations for dispensing, counseling, and patient safety. You will gain clarity on when ranitidine may be appropriate for use (again) and how to guide patients confidently in its safe use.

Learning Objectives

Upon successful completion of this course, pharmacists should be able to:
1. Summarize the major safety and regulatory issues that prompted ranitidine’s withdrawal, and the changes made in the reformulated product approved in 2025.
2. Describe pharmacist-relevant considerations for dispensing, patient counseling, and transition from alternative acid-reducing therapies.

Faculty

Rachel Maynard, PharmD

GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

Disclosures:

Rachel Maynard has no relevant financial relationships with ineligible companies to disclose.

K. Ashley Garling-Nanez, PharmD

Assistant Director of Program
UT Center of Health Communications

Disclosures:

K. Ashley Garling-Nanez has no relevant financial relationships with ineligible companies to disclose.

Course Details